
What smart money is saying about Heartflow, Inc.
3 funds in our archive have pitched Heartflow, Inc. — most recently Baron Discovery Fund in March 2026.
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.
Fund coverage · 3 theses
- Baron Discovery FundMarch 2026
Heartflow develops FDA-approved AI software for non-invasive coronary analysis with strong customer trust and resilience to AI disintermediation.
Read the full thesis - Baron Opportunity FundDecember 2025
Heartflow, Inc. is an AI-powered cardiac diagnostics company with a deep data moat, regulatory approvals, and early penetration supporting scalable, high-margin growth.
Read the full thesis - Baron Global Opportunity FundSeptember 2025
Heartflow, Inc. is a promising medical device company leveraging AI to accurately diagnose heart disease, addressing a critical need in healthcare with significant growth potential and a strong competitive advantage.
Read the full thesis
Read every full thesis on Heartflow, Inc.
Unlock all 3 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→